16,739,076 Equity Shares of Dr. Lal PathLabs Limited are subject to a Lock-Up Agreement Ending on 20-DEC-2018.
December 19, 2018
Share
16,739,076 Equity Shares of Dr. Lal PathLabs Limited are subject to a Lock-Up Agreement Ending on 20-DEC-2018. These Equity Shares will be under lockup for 1096 days starting from 20-DEC-2015 to 20-DEC-2018.
Details:
A total of 9,817,018; 6,254,491 and 667,567 shares held by Arvind Lal, Vandana Lal, and Eskay House (HUF), the promoters of the company, will be under lock-up for a period of three years from the date of allotment in the issue, December 20, 2015.
The entire remaining pre-issue equity share capital of the company, except for the shares held by persons who are employees of company as on the date of allotment pursuant to allotment under ESOP 2005 and ESOP 2010 or transfers under ESPS 2015, will be under lock-up for a period of one year from the date of allotment in the issue.
An aggregate of 3480000 shares will be under lock-up for a period of 30 days from the allotment date.
Dr. Lal PathLabs Limited is an India-based company that is engaged in providing diagnostic and related healthcare tests and services. The Company is engaged in the business of running laboratories for carrying out pathological investigations of various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It offers a range of tests by condition, which includes allergy, diabetes, health checkups, viral infections, fever, heart diseases, hypertension, cancer, abortions, anemia, arthritis, breast cancer, diphtheria, disorder of the liver, disorders of bone, drugs of abuse, infertility, lymphoma, tuberculosis, ovarian cancer, osteoporosis, multiple sclerosis, muscular disorder, and viral infections. The Companyâs subsidiaries include Paliwal Diagnostics Private Limited, Paliwal Medicare Private Limited, and Dr. Lal PathLabs Nepal Private Limited.
DR. LAL PATHLABS LIMITED 
